Pharmaceutical companies' interest in RNA interference is waning, says The New York Times' Andrew Pollack. Roche, Pfizer, and Abbott have all ceased to work on RNAi, though Roche's Klaus Stein says that he has "no doubt that at a certain point in time RNAi will make it to the market," but that there were "opportunities that have higher priorities" to focus on. Pollack adds that it is fairly common for a new technique to enjoy a moment of vogue before some interest in it is lost.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.